哌罗匹隆
哌罗匹隆 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 溶于二甲基亚砜 |
| 形态 | 固体 |
| 颜色 | 白色至类白色 |
| InChI | InChI=1/C23H30N4O2S/c28-22-17-7-1-2-8-18(17)23(29)27(22)12-6-5-11-25-13-15-26(16-14-25)21-19-9-3-4-10-20(19)30-24-21/h3-4,9-10,17-18H,1-2,5-8,11-16H2/t17-,18+ |
| InChIKey | FBVFZWUMDDXLLG-HDICACEKNA-N |
| SMILES | C1(=O)[C@]2([H])[C@@]([H])(CCCC2)C(=O)N1CCCCN1CCN(C2C3=C(SN=2)C=CC=C3)CC1 |&1:2,4,r| |
哌罗匹隆 用途与合成方法
|
5-HT 2A Receptor 0.6 nM (Ki) |
Dopamine D 2 1.4 nM (Ki) |
5-HT 1A Receptor 2.9 nM (Ki) |
5-HT 1 Receptor 18 nM (Ki) |
Dopamine D 1 41 nM (Ki) |
Perospirone (SM-9018 free base) possesses moderate affinities for α 1 , 5-HT 1 , and D 1 receptors (K i =17, 18 and 41 nM, respectively) .
Perospirone (SM-9018 free base; 1.0-10.0 mg/kg/day; orally; for 14 consecutive days) significantly attenuates PCP-induced cognitive deficits in mice in a dose-dependent manner.
| Animal Model: | Male ICR mice (6 weeks old) weighing 25-30 g |
| Dosage: | 1.0, 3.0 or 10.0 mg/kg |
| Administration: | Orally; daily; for 14 consecutive days |
| Result: | Significantly attenuated PCP-induced cognitive deficits in mice in a dose-dependent manner. |
哌罗匹隆 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2025-12-22 | HY-B0731A | 哌罗匹隆 | 150915-41-6 | 5mg | 700 |
| 2025-12-22 | HY-B0731A | 哌罗匹隆 | 150915-41-6 | 10mM * 1mLin DMSO | 770 |
